Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Phase 2
1(25.0%)
4Total
Phase 1(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04201574Phase 1Completed

Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease

Role: lead

NCT04899518Phase 2Completed

ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease

Role: lead

NCT03452033Phase 1Completed

H-1337 Ophthalmic Solution Phase 1/2

Role: lead

NCT04855565Phase 1Terminated

ALY688-SR in Generally Healthy Overweight or Obese Adults

Role: lead

All 4 trials loaded